Oncology Brothers: Practice-Changing Cancer Discussions

We dived deep into the rapidly evolving landscape of second-line and beyond treatment options for multiple myeloma. In this episode, we were joined by esteemed experts Beth Faiman, PhD, CNP, Vincent Rajkumar, MD, and Rafael Fonseca, MD, who shared their insights on the latest advancements in bispecific antibodies, CAR-T therapies, and immunomodulatory agents.
 
Discover the current treatment algorithms for relapsed multiple myeloma, including the role of triplet therapies, the significance of the MajesTEC-3 and MajesTEC-9 studies, and the clinical implications of new data. The discussion also covered the importance of managing side effects, the necessity of collaboration between community oncologists and academic centers, and the future of treatment in this dynamic field.
 
Whether you're a healthcare professional or someone interested in the latest in cancer treatment, this episode provides valuable insights into the future of multiple myeloma therapy.
 
Topics Covered:
Current treatment options for relapsed multiple myeloma
Insights from the MajesTEC-3 and MajesTEC-9 studies
The role of bispecific antibodies and CAR-T therapies
Managing side effects and patient care strategies
The importance of community and academic partnerships
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers
Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/ 
 
Tune in now and stay informed about the latest in oncology!
#MultipleMyeloma, #BispecificAntibody, #CARTtherapy, #CELMoDs, #OncologyBrothers
 

Welcome to the Oncology Brothers podcast! In this episode, we dived into a challenging case series focused on kidney cancer, featuring special guest Dr. Pedro Barata, a GU medical oncologist from the University Hospitals.
We had the opportunity to explore two real-life cases that highlighted the complexities of treatment decisions in metastatic renal cell carcinoma (RCC). We discussed the latest frontline options, including immunotherapy and targeted therapy combinations, and how to choose the best approach based on patient characteristics and disease progression.
Key topics covered in this episode included:
The role of next-generation sequencing (NGS) in guiding treatment options
Choosing between dual checkpoint inhibitors and IO-TKI combinations
Managing side effects associated with various treatment regimens
Sequencing treatment options for patients who progress after initial therapy
Insights into the latest data on emerging therapies like Belzutifan and Lenvatinib
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more challenging case discussions and treatment algorithms!
#KidneyCancer, #RenalCellCarcinoma, #RCC, #Immunotherapy, #TKI, #OncologyBrothers

Welcome to this episode of Oncology Brothers, where we dived into the latest advancements in GU malignancies! We welcomed esteemed guests Dr. Brian Rini and Dr. Thomas Powles, both GU medical oncologists and co-hosts of the Uromigos podcast.
 
In this episode, we discussed key studies presented at ASCO 2026 that are set to change clinical practice in prostate, kidney and bladder cancer, and recent FDA approvals in the GU space:
PROTEUS:  trial comparing ADT monotherapy to apalutamide plus ADT in high-risk localized prostate cancer. We explored its findings, implications, and the ongoing debate surrounding its control arm.
TALAPRO-3 Study: impact of PARP inhibitors combined with enzalutamide in metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) mutations. We discussed the nuances of HRR mutations and their clinical significance.
CAPITELLO-281: insights into the recent approval of this AKT inhibitor for metastatic castration-sensitive prostate cancer with PTEN loss, based on the CAPItello-281 study.
EV-302 update: combination of EV-pembrolizumab still maintains the doubling of survival benefit with longterm follow up.
POTOMAC: durvalumab + BCG induction therapy for high-risk non-muscle invasive bladder cancer (NMIBC) could be a choice for a selected patient population.
LITESPARK-022: The new approval of belzutifan with pembrolizumab in the adjuvant setting, discussing its efficacy and the importance of patient selection.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966
 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/ 
 
Throughout the episode, we emphasized the importance of balancing treatment benefits with potential adverse events, as well as the need for shared decision-making in clinical practice.
#GUOncology, #ASCO2026, #ProstateCancer, #BladderCancer, #RenalCellCarcinoma, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Nina Sanford, a GI radiation oncologist from UT Southwestern, to discuss a critical topic in cancer treatment: when to hold and not to hold systemic therapy during radiation and for how long.
 
Join us as we explore:
The framework for balancing systemic therapy with different types of radiation, including SBRT, palliative, and conventional radiation.
Insights on managing cytotoxic chemotherapy, immunotherapy, TKIs, and targeted therapies in conjunction with radiation.
The importance of individualized treatment plans and the evolving data around various drug classes, including BRAF inhibitors, PARP inhibitors, and anti-HER2 therapies.
Practical recommendations for community oncologists navigating these complex decisions.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/
Don't forget to check out Dr. Sanford's teaching video for more in-depth information!
#RadiationOncology, #SystemicTherapy, #SBRT, #MultidisciplinaryCare, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode we are joined by Dr. Neena Vijayvergia from Fox Chase Cancer Center to discuss the latest highlights from ASCO 2026, focusing on gastrointestinal (GI) studies.
 
We discussed key studies:
EMERALD-3 in HCC: Exploring the findings on combining TACE with Durvalumab and Tremelimumab, and the implications for patient outcomes.
FIGHT-302 in Cholangiocarcinoma: The potential of FGFR inhibitors in frontline settings and the challenges of biomarker testing.
CIRCULATE Update: The role of ctDNA in stage 2 colon cancer and how it influences treatment decisions.
MATTERHORN Update: Benefits of perioperative chemotherapy and the importance of maintaining treatment regimens for better patient outcomes.
We also touched on the evolving landscape of GI malignancies and the significance of multidisciplinary approaches in treatment planning.
Tune in for an informative discussion that aims to enhance your understanding of the latest advancements in oncology and their practical applications in the clinic. 
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to subscribe for more updates on treatment algorithms, challenging cases, and conference highlights!
#ASCO2026, #GIOncology, #ctDNA, #FGFRinhibitor, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived deep into the groundbreaking RASolute 302 study on pancreatic cancer, featuring special guest Dr. Brian Wolpin, a leading oncologist from Dana-Farber Cancer Institute.
 
We discussed:
The significance of RAS mutations in pancreatic cancer, which affect over 90% of patients.
The trial design and key findings of the RASolute 302 study, highlighting the impressive doubling of overall survival from 6.6 months to 13.2 months with the new drug, Daraxonrasib.
The mechanism of action of Daraxonrasib as a RAS-on inhibitor and its unique properties compared to other RAS inhibitors.
Common side effects associated with the drug, including rash, diarrhea, and stomatitis, and strategies for managing these in clinical practice.
The importance of biomarker testing and the implications for treatment in all pancreatic cancer patients.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Tune in to learn how this new therapy could change the landscape of treatment for pancreatic cancer patients. Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in cancer research and treatment!#PancreaticCancer, #Daraxonrasib, #ASCO2026, #RASmutation, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we dived into the key highlights from ASCO 2026, focusing on groundbreaking studies in head and neck cancer and sarcoma.
Join us as we discuss:
Nasopharyngeal Carcinoma: comparing carboplatin and cisplatin in induction and concurrent chemoradiation therapy. Can we extrapolate these findings to other head and neck cancers?
Amivantamab in Head and Neck Cancer: Insights from the OrigAMI4 study, showcasing the efficacy of amivantamab in refractory settings, with an impressive overall response rate of 47%.
SARC041: A look at abemaciclib as a treatment for de-differentiated liposarcoma, highlighting significant improvements in progression-free survival.
Gastrointestinal Stromal Tumors (GIST): The PEAK trial results, explored the combination of bezuclastinib and sunitinib after progression on imatinib, showing promising outcomes.
 
We are thrilled to have Dr. Ari Rosenberg from the University of Chicago and Dr. Sam Armstrong from Indiana University join us to share their expertise and insights on these important studies.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
 
Follow us on social media:
•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ 
 
Tune in for an informative discussion that sheds light on the latest advancements in oncology! Don’t forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers.
 
#ASCO2026, #HeadAndNeckCancer, #Sarcoma, #GIST, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we discussed challenging cases focused on metastatic non-small cell lung cancer (NSCLC) with common EGFR mutations. Joined by experts Dr. Shirish Gadgeel from the Emory University and Dr. Wade Iams from Tennessee Oncology, the discussion revolved around two real-life patient cases.
The first case featured a 54-year-old gentleman with active tobacco use and diffusely metastatic NSCLC, including an isolated brain lesion. The panel explored treatment options, including single-agent osimertinib versus dual combinations of amivantamab-lazertinib and osimertinib-chemotherapy, emphasizing the importance of shared decision-making and considering co-mutations and patient demographics.
In the second case, the conversation shifted to supportive care and managing side effects, particularly focusing on skin toxicity associated with amivantamab. The experts shared their proactive approaches to patient education and the significance of monitoring and adjusting treatment plans to enhance patient quality of life.
 
Key Points:
In EGFR-mutated NSCLC with CNS metastases, treatment selection between single-agent osimertinib and combination amivantamab-lazertinib vs. osimertinib-chemotherapy requires individualized consideration of age, co-mutations, extent of disease, and patient preference rather than mutation status alone.
Younger patients with CNS disease may benefit from more aggressive upfront combination therapy, while shared decision-making remains central to navigating the expanded efficacy versus increased toxicity trade-off.
Dermatologic toxicities associated with amivantamab requires proactive management including supportive care regimen, early dose adjustments and close patient monitoring to maintain treatment continuity.
Providing the best available upfront therapy in metastatic EGFR-mutated NSCLC is critical, as sequencing options become more limited at progression.
Join us for an insightful discussion on the latest treatment algorithms, the importance of personalized care, and the evolving landscape of NSCLC management.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966
 
Follow us on social media:
⁠X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to subscribe for more episodes featuring conference highlights and challenging cases in oncology!
#EGFRMutated, #LungCancer, #ThoracicOncology, #PersonalizedMedicine, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Isabel Preeshagul from Memorial Sloan-Kettering to discuss the latest advancements in lung cancer presented at ASCO 2026.
 
We dived into four key studies that could change clinical practice:
LIBRETTO-432: exploring the promising event-free survival data with selpercatinib in RET-positive disease and its implications for adjuvant therapy.
CROWN 7yr Update: seven-year progression-free survival results with lorlatinib in ALK-positive non-small cell lung cancer and the associated side effects.
CHRYSALIS-2: exciting findings regarding amivantamab for atypical EGFR mutations and its potential to become the new standard of care.
HARMONi-6: dual-headed drug ivonescimab combined with chemotherapy in metastatic squamous cell lung cancer and its intriguing results.
We also touched on the importance of molecular testing for all patients, regardless of stage or histology, and highlighted the latest updates on tarlatamab in small cell lung cancer.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://twitter.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Tune in for an insightful discussion that aims to keep our oncology community informed and engaged with the latest research and treatment options!
Don't forget to like, subscribe, and check out our other episodes for more insights on oncology treatments, conference highlights, and FDA approvals.
#ASCO2026, #LungCancer, #ALKPositive, #RETPositive, #OncologyBrothers

Join us as we bring you the latest insights from ASCO 2026! In this episode, we dived deep into the groundbreaking RASolute-302 study, which has made waves in the treatment of metastatic pancreatic cancer. Discover how the novel RAS inhibitor, Daraxonrasib, has doubled overall survival rates from 6.7 months to an impressive 13.2 months for patients in the second-line setting.
 
We were joined by esteemed experts Dr. Rachna Shroff, Dr. Shubham Pant, Dr. Eileen O'Reilly, and Dr. Andrew Ko, who shared their insights on the study's design, findings, and the implications for our clinical practice. We touched on the prevalence of RAS mutations in pancreatic cancer, the mechanism of action of Daraxonrasib, and the side effect profile that clinicians need to manage effectively.
Topics Covered:
Overview of the RASolute-302 study
Impact of Daraxonrasib on overall survival
RAS mutations in pancreatic cancer
Mechanism of action of RAS inhibitors
Side effects and management strategies
Tune in now for an enlightening discussion on the future of pancreatic cancer treatment!
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://twitter.com/oncbrothers
⁠Instagram: https://www.instagram.com/oncbrothers
Website: https://oncbrothers.com/ 
 
#ASCO2026, #PancreaticCancer, #Daraxonrasib, #RASmutation, #OverallSurvival